pyrazolanthrone has been researched along with diallyl disulfide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, XX; Lin, M; Ma, YH; Su, Q; Tan, H; Tang, Y; Wen, L; Yi, L | 1 |
| Bauer, D; Darling-Reed, S; Day, A; Flores-Rozas, H; Mazzio, E; Redmon, N; Reuben, JS; Sadrud-Din, S; Soliman, KF; Taka, E | 1 |
2 other study(ies) available for pyrazolanthrone and diallyl disulfide
| Article | Year |
|---|---|
Diallyl disulfide induces apoptosis in human leukemia HL-60 cells through activation of JNK mediated by reactive oxygen.
Topics: Allyl Compounds; Anthracenes; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Blotting, Western; Cell Proliferation; Cell Survival; Disulfides; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Flow Cytometry; HL-60 Cells; Humans; Indicators and Reagents; JNK Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Reactive Oxygen Species | 2010 |
Diallyl disulfide inhibits TNFα induced CCL2 release through MAPK/ERK and NF-Kappa-B signaling.
Topics: Allyl Compounds; Anthracenes; Anticarcinogenic Agents; Butadienes; Cell Line, Tumor; Chemokine CCL2; Disulfides; Garlic; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Macrophages; MAP Kinase Kinase 4; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; NF-kappa B p50 Subunit; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Tumor Necrosis Factor-alpha | 2015 |